Teclistamab-cqyv
Teclistamab-cqyv works by bringing healthy T cells (immune cells that help kill cancer cells) and myeloma cells close together so the T cells can more effectively kill the myeloma cells. It does this by binding to a protein called CD3 on healthy T cells and to a protein called BCMA on myeloma cells. Teclistamab-cqyv is a type of targeted therapy drug called a bispecific T-cell engager (BiTE).
FDA label information for this drug is available at DailyMed.
Use in Cancer
Teclistamab-cqyv is approved to treat:
- Multiple myeloma that has come back or did not respond to treatment. It is used:
- with daratumumab and hyaluronidase-fihji in adults who have received at least one treatment that included an immunomodulating agent and a proteasome inhibitor
- alone in adults who have received at least four treatments that included an immunomodulating agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
Teclistamab-cqyv is only available as part of a special program called Tecvayli and Talvey Risk Evaluation and Mitigation Strategies (REMS).
Teclistamab-cqyv is also being studied in the treatment of other types of cancer.
More About Teclistamab-cqyv
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Teclistamab-cqyv. - A lay language summary of important information about this drug.
Research Results and Related Resources
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Teclistamab-cqyv - Check for trials from NCI's list of cancer clinical trials now accepting patients.